Novartis Ag

Nektar Therapeutics

Inhale Therapeutic Systems, Inc.

Novartis Pharma Ag

Andrew Clark

Carlos A Schuler

Marc S Gordon

Thomas K Brewer

William W Alston

Steve Paboojian

Kevin Russert Walsh

Jeffry G Weers

Frank W Ingle

Mei-chang Kuo

Thomas E Tarara

Adrian Edward Smith

Don S Minami

Kevin S Nason

Michael A Eldon

Scot Cheu

Dennis Rasmussen

Derrick Tuttle

George H Foulds

William Leung

Aneesh Bakshi

Brian R S Ward

Rangachari Narashimhan

Andrea Rourke

Derrick J Tuttle

Dennis R Rasmussen

Joanne Curley

Methods for preparing dry powders having hydrophobic and hydrophilic components comprise combining solutions of the components and spray drying them simultaneously in a spray dryer. The hydrophilic and hydrophobic component are separately dissolved in separate solvents and directed simultaneously through a nozzle, usually a coaxial nozzle, into the spray dryer. The method provides dry powders having relatively uniform characteristics.

Systems and processes for spray drying hydrophobic and hydrophilic components

A package for storing an aerosolizable pharmaceutical formulation comprises a capsule adapted to contain the aerosolizable pharmaceutical formulation, and a moisture barrier around the capsule. The moisture barrier comprises a material that is resistant to moisture passage, whereby the moisture barrier reduces the amount of moisture in contact with the aerosolizable pharmaceutical formulation so that the aerosolizable pharmaceutical formulation may be aerosolized when the capsule is opened. In one version, the moisture barrier comprises a metal.

Capsule package with moisture barrier

The present invention is directed to methods and devices for delivering an active agent formulation to the lung of a human patient. The active agent formulation may be in dry powder form, it may be nebulized, or it may be in admixture with a propellant. The active agent formulation is delivered to a patient at a low inspiratory flow rate for an initial period of time to increase bioavailability of the active agent.

Flow resistance modulated aerosolized active agent delivery

Formulations are provided for pulmonary administration of an antifungal agent to a patient. Methods of using the formulations in the treatment of antifungal infections are also provided, including treatment of pulmonary aspergillosis with amphotericin B-containing formulations. Methods of manufacturing the formulations to achieve optimum properties are provided as well.

Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use

An aerosolization apparatus comprises a container containing a pharmaceutical formulation, the pharmaceutical formulation comprising an active agent and a propellant. The aerosolization apparatus further comprises a metering chamber in communication with the container, the metering chamber adapted to hold a metered amount of the pharmaceutical formulation, a valve to allow the metered amount of the pharmaceutical formulation to be released from the metering chamber when the valve is actuated, and a pressurizer that applies pressure to the pharmaceutical formulation in the metering chamber while the pharmaceutical formulation is being released from the metering chamber. In one version, the metering chamber is sized so that at least 2 mg, and preferably at least 5 mg, of the active agent is be aerosolized for delivery to a user during inhalation.

Increased dosage metered dose inhaler

A method for aerosolizing a powder utilizes a receptacle having a cavity containing a powder. An access end of an extraction tube is inserted into the cavity, and an inlet opening is formed in the receptacle. A pressurized gas is flowed through the inlet opening, through the cavity and through the extraction tube to move the powder in the cavity into the extraction tube where the powder is entrained in the gas to form an aerosol.

Systems and methods for extracting powders from receptacles

The present invention is directed to methods and devices for delivering an active agent formulation to the lung of a human patient. The active agent formulation may be in dry powder form, it may be nebulized, or it may be in admixture with a propellant. The active agent formulation is delivered to a patient at an inspiratory flow rate of less than 17 liters per minute. The bioavailability of the active agent was found to increase at these flow rates when compared to inspiratory flow rates of 17 liters per minute or more.

Aerosolized active agent delivery

Systems and methods are provided for aerosolizing a pharmaceutical formulation. According to one method, respiratory gases are prevented from flowing to the lungs when attempting to inhale. Then, respiratory gases are abruptly permitted to flow to the lungs. The flow of respiratory gases may then be used to extract a pharmaceutical formulation from a receptacle and to place the pharmaceutical formulation within the flow of respiratory gases to form an aerosol.

Systems and methods for aerosolizing pharmaceutical formulations

Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients

Systems and processes for spray drying hydrophobic drugs with

Growing community of inventors

Woodside, CA, United States of America

Andrew Clark